<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095704</url>
  </required_header>
  <id_info>
    <org_study_id>CSU-YXY-001</org_study_id>
    <nct_id>NCT02095704</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of a Standard Paracetamol Tablet and Oral Solution After Oral Administration in Chinese Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug dissolution in vivo play a crucial role for the bioavailability and therapeutic of an&#xD;
      orally administered solid dosage form. The aim of this study was to evaluate the&#xD;
      pharmacokinetics of a standard paracetamol tablet in comparison with oral solution in Chinese&#xD;
      healthy volunteers. Based on the Noyes-Whitney equation and pharmacokinetics parameters,&#xD;
      investigators trend to propose a method to estimate in vivo dissolution time and dissolution&#xD;
      kinetics of solid dosage form.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>one month</time_frame>
    <description>AUC:the area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>one month</time_frame>
    <description>Cmax: maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>one month</time_frame>
    <description>Tmax: the time point of maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT</measure>
    <time_frame>one month</time_frame>
    <description>MRT: mean residence time</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Focus of Study: Pharmacokinetics Analysis, in Vivo Dissolution Studies</condition>
  <arm_group>
    <arm_group_label>paracetamol oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paracetamol tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol oral solution</intervention_name>
    <description>dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose</description>
    <arm_group_label>paracetamol oral solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol tablet</intervention_name>
    <description>dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose</description>
    <arm_group_label>paracetamol tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sex: Male or female (limited to PK study)&#xD;
&#xD;
          2. Healthy volunteers, age: 18-45（medical history, physical examination, vital signs, ECG&#xD;
             and lab tests are qualified during screening）&#xD;
&#xD;
          3. Body Mass Index（BMI）:19~24 or body weight is not less than 50Kg&#xD;
&#xD;
          4. Non-pregnant women confirmed by pregnancy test&#xD;
&#xD;
          5. Vital Signs: after 3 minutes supination, the following measurements criteria should be&#xD;
             within ranges: body temperature (axillary temperature), 36.0~37.0 ℃; blood pressure,&#xD;
             SBP 90~140mmHg（12.0~18.7kpa）and DBP 60~90mmHg（8.0~12.0kpa）; arterial pulse: 60~100 bpm&#xD;
&#xD;
          6. Non-hypersensitivity to this product or its similar product&#xD;
&#xD;
          7. Non-smoker, non-alcoholic&#xD;
&#xD;
          8. Subject must be able to sign Inform Consent prior to participation into this study&#xD;
&#xD;
          9. Subject must be able to communicate with investigator and comply with study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meet with one or several of the following criteria should be excluded:&#xD;
&#xD;
          1. Subjects failed in physical examination&#xD;
&#xD;
          2. Pregnant or nursing women&#xD;
&#xD;
          3. Administration of a known drug that can cause damage to organs within 3 months&#xD;
&#xD;
          4. Administration of any prescription drug or non-prescription drug 2 weeks before&#xD;
             initial dose&#xD;
&#xD;
          5. Before initial dose, participation in any other clinical trials within 3 months&#xD;
&#xD;
          6. Blood donation 3 months before this study, or plan to have blood donation during or&#xD;
             one month after this study&#xD;
&#xD;
          7. Diagnosis of clinical evident diseases 2 weeks before initial dose&#xD;
&#xD;
          8. Primary diseases to vital organs&#xD;
&#xD;
          9. Physically or mentally disabled&#xD;
&#xD;
         10. Medical history of specific allergy (asthma, measles, eczematous dermatitis), or known&#xD;
             to allergic to similar (including excipients)&#xD;
&#xD;
         11. Any other surgical or internal medicinal conditions that might cause damage to study&#xD;
             subjects or will change the absorption, distribution, metabolism and elimination of&#xD;
             investigational drug, including:&#xD;
&#xD;
               -  inflammatory intestinal syndrome, peptic ulcer, alimentary tract hemorrhage&#xD;
&#xD;
               -  a history of severe gastrointestinal tract operation, such as gastrectomy,&#xD;
                  gastrosmoty / jejunostomy or large bowel resection&#xD;
&#xD;
               -  a history of hepatic disease or laboratory examination findings such as ALT, AST,&#xD;
                  γ-GT or T-Bili showing clinically significant abnormalities to liver&#xD;
&#xD;
               -  a history of renal disease or laboratory examination findings such as creatinine,&#xD;
                  urea nitrogen, or albuminuria showing clinically significant abnormalities to&#xD;
                  kidney&#xD;
&#xD;
               -  urination disorder or dysuresia.&#xD;
&#xD;
         12. A history of immunological deficiency disease, or HIV positive&#xD;
&#xD;
         13. HBV or HCV positive&#xD;
&#xD;
         14. Women undergone menstrual period during study&#xD;
&#xD;
         15. Consumption of a significant amount of smoking or drinking, that is drinking more than&#xD;
             28 units of alcohol per week (1 unit: 285ml of beer, 25ml of liquor, or 1 glass of&#xD;
             wine), or smoking more than 2 cigarettes&#xD;
&#xD;
         16. Frequent use of sedatives, hypnotics, stabilizers or other addictive drugs&#xD;
&#xD;
         17. Consumption of more than 8 cups of tea, coffee, and or caffeine beverages&#xD;
&#xD;
         18. Unable to complete this study for any others reasons.&#xD;
&#xD;
         19. Investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Feifan Xie</investigator_full_name>
    <investigator_title>Institute of Drug Metabolism and Pharmacokinetics,School of Pharmaceutical Sciences,Central South University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

